Screener
Incyte INCY Product royalty revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Incyte’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000879169-26-000056
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Net sales | $1,488,149 | $1,059,414 | $2,592,633 | $1,981,688 |
| Product royalty revenues | 174,690 | 151,115 | 325,882 | 281,739 |
| Milestone and contract revenues | 11,200 | 5,000 | 28,200 | 5,000 |
| Total revenues | 1,674,039 | 1,215,529 | 2,946,715 | 2,268,427 |
| Costs, expenses and other: | ||||
| Cost of sales (including definite-lived intangible amortization) | 104,957 | 78,766 | 209,480 | 151,954 |
| Contract dispute settlement | — | (242,251) | — | (242,251) |
Item 1. Financial Statements
FAQ
- What is Incyte's product royalty revenues — total revenues?
- Incyte (INCY) reported product royalty revenues — total revenues of $174.69M in Q2 2026.
- How has Incyte's product royalty revenues — total revenues changed year-over-year?
- Incyte's product royalty revenues — total revenues increased by 15.6% year-over-year, from $151.12M to $174.69M.
- What is the long-term trend for Incyte's product royalty revenues — total revenues?
- Over 4 years (2021 to 2025), Incyte's product royalty revenues — total revenues has grown at a 2.8% compound annual growth rate (CAGR), from $569.26M to $636.91M.
- What does product royalty revenues — total revenues mean?
- This metric represents the total revenue generated from licensing intellectual property and drug development rights to third-party partners. It reflects the income stream derived from royalties on net sales of products developed by Incyte but commercialized by external pharmaceutical companies. This segment is a key indicator of the firm's ability to monetize its research and development pipeline through strategic partnerships.
Ask your AI about Incyte's product royalty revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude